Product image of Letrozole Crescent Pharma (Letrozole) supplied by GNH India

Letrozole Crescent Pharma

Active Ingredient:
Letrozole
Origin:
EU

Letrozole Crescent Pharma (Letrozole)

Letrozole, the active ingredient in Letrozole Crescent Pharma, is an aromatase inhibitor presented as a tablet for oral use. It works by selectively inhibiting the aromatase enzyme, thereby reducing peripheral conversion of androgens to estrogens. It lowers estrogen production and is used to treat hormone receptor‑positive breast cancer in postmenopausal women.

GNH India supplies Letrozole Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company provides bulk and packaged quantities to hospitals, pharmacies and procurement teams under strict quality standards.

Manufacturer / TM Owner

Crescent Pharma Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Letrozole is indicated for hormone‑driven breast cancer pathways, primarily in postmenopausal patients.
  • Hormone receptor‑positive breast cancer (postmenopausal): reduces risk of disease recurrence and progression.
  • Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer (postmenopausal): improves disease‑free survival.
  • Metastatic hormone receptor‑positive breast cancer (postmenopausal): delays tumor growth.

How It Works

  • Letrozole binds to the aromatase enzyme (CYP19A1) and blocks its activity, preventing the conversion of androstenedione and testosterone into estrone and estradiol. By lowering circulating estrogen levels, it deprives estrogen‑dependent tumor cells of a growth stimulus, thereby inhibiting proliferation of hormone‑sensitive breast cancer cells.

Side Effects

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Hot flashes: transient episodes of increased skin temperature.
  • Joint and muscle pain: arthralgia or myalgia often reported.
  • Fatigue: persistent tiredness affecting daily activities.
  • Nausea: mild to moderate gastrointestinal upset.
  • Increased cholesterol: elevation of serum lipid levels.
  • Bone density loss: reduced bone mineral density over time.

Serious or Rare Side Effects

  • Severe liver injury: jaundice or hepatitis requiring monitoring.
  • Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
  • Osteoporotic fractures: increased risk of hip or vertebral fractures.
  • Cardiovascular events: myocardial infarction or stroke.
  • Allergic reactions: rash, angioedema, or anaphylaxis.

Precautions & Warnings

  • Before initiating letrozole therapy, clinicians should evaluate several safety considerations.
  • Monitor bone health: assess risk of osteoporosis and consider calcium/vitamin D supplementation.
  • Assess cardiovascular risk: watch for hypertension or thromboembolic events.
  • Check liver function: adjust use if hepatic impairment is present.
  • Avoid use in pregnancy: teratogenic risk; contraindicated in pregnant or nursing women.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Avoid Interactions

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Concurrent estrogen‑containing hormone therapy: negates therapeutic effect.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce plasma levels.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity.

Moderate Interactions (Monitor Closely)

  • Tamoxifen: potential antagonistic effect on estrogen pathways.
  • Warfarin: possible alteration of anticoagulant effect.
  • Antidepressants metabolized by CYP2A6: monitor for altered levels.

Frequently Asked Questions

Letrozole Crescent Pharma is used to treat hormone receptor‑positive breast cancer in postmenopausal women. It is prescribed as part of adjuvant therapy to reduce the risk of recurrence, as well as for metastatic disease to slow tumor progression.

Letrozole inhibits the aromatase enzyme, which is responsible for converting androgens into estrogens in peripheral tissues. By blocking this conversion, estrogen levels fall, depriving estrogen‑dependent cancer cells of a growth signal and thereby limiting tumor growth.

The specific dose of letrozole is determined by the prescribing clinician based on the patient’s clinical condition, renal and hepatic function, and treatment goals. Dosage regimens are individualized and should follow the prescriber’s instructions.

Letrozole is classified as Pregnancy Category X, indicating it is contraindicated during pregnancy because of known teratogenic risk. It is also not recommended while breastfeeding, as it may pass into breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole is a third‑generation aromatase inhibitor with a high potency and a long half‑life, offering once‑daily dosing. Compared with anastrozole or exemestane, letrozole often shows slightly greater estrogen suppression, but choice depends on individual patient tolerance, drug‑interaction profile, and physician preference.

Store the tablets at ambient temperature, preferably below 25 °C. Keep the container tightly closed, protect from moisture and direct light, and store out of reach of children.

Letrozole is taken orally, usually with or without food, as a single tablet per day. The tablet should be swallowed whole with water and not chewed or crushed.

Serious risks include severe liver injury, venous thromboembolism, osteoporotic fractures, and cardiovascular events such as myocardial infarction or stroke. Patients should be monitored regularly for signs of these conditions, and any concerning symptoms should be reported promptly.

Letrozole should not be used by pregnant or breastfeeding women, premenopausal patients, or individuals with known hypersensitivity to letrozole or any component of the formulation. Caution is also advised in patients with severe hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT